Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)
Study sponsor: Fulcrum Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-11-07Actual
Enrollment · participants76Actual
Source updated2025-09-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.